Single Dose of 9-cis-retinoic Acid in Hepatic Patients

June 28, 2013 updated by: Frederik Grønlund MD DMSci, University Hospital, Gentofte, Copenhagen

The Pharmacokinetics of a Single Dose of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Moderate to Severe Hepatic Insufficiency

To test whether patients with hepatic insufficiency can tolerate one oral dose of 9-cis-retinoic acid and to test whether the metabolism of retinoic acid is altered.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Gentofte, Denmark, 2900
        • Gentofte Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

10 patients with hepatic disease and 10 controls

Description

Inclusion Criteria:

  1. Have biopsy verified hepatic insufficiency
  2. Medically stable.
  3. Ultra sonic examination of lever within the past 3 months
  4. No pregnancy documented in women. use of anticonception during study and 1 month after

Exclusion criteria:

  1. Odd blood counts and samples not related to hepatic disease
  2. encephalopathy (> grad II)
  3. concomitant treatment with pharmaca that is metabolized by CYP3A4 in the liver.
  4. Cardiac disease
  5. Kidney disease
  6. Epilepsia
  7. Stroke
  8. Esophagal bleeding
  9. Severe ascites
  10. HIV-positivity
  11. Psychiatric disorder
  12. Cancer
  13. pregnancy or lactating women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Hepatic patients
patients with hepatic insufficiency
Drug: 9-cis-retinoic acid
Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure
Healthy Controls
Healthy adults
Drug: 9-cis-retinoic acid
Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
A comparison of the metabolisation of retinoic acid in patients with hepatic insufficiency and controls
Time Frame: 24 hours
Analysis on samples
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Gentofte, Copenhagen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2010

Primary Completion (Actual)

June 1, 2012

Study Completion (Actual)

June 1, 2012

Study Registration Dates

First Submitted

June 21, 2013

First Submitted That Met QC Criteria

June 28, 2013

First Posted (Estimate)

July 3, 2013

Study Record Updates

Last Update Posted (Estimate)

July 3, 2013

Last Update Submitted That Met QC Criteria

June 28, 2013

Last Verified

June 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2010-338
  • Allitretinoin

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatic Insufficiency

Clinical Trials on 9-cis-retinoic acid

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe